- Home
- INZY vs UROY Comparison
INZY vs UROY Comparison
Compare INZY & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- UROY
- Stock Information
- Founded
- INZY 2015
- UROY 2017
- Country
- INZY United States
- UROY Canada
- Employees
- INZY N/A
- UROY N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- UROY
- Sector
- INZY Health Care
- UROY
- Exchange
- INZY Nasdaq
- UROY Nasdaq
- Market Cap
- INZY 321.4M
- UROY 351.1M
- IPO Year
- INZY 2020
- UROY N/A
- Fundamental
- Price
- INZY $3.13
- UROY $2.56
- Analyst Decision
- INZY Strong Buy
- UROY Strong Buy
- Analyst Count
- INZY 7
- UROY 2
- Target Price
- INZY $16.14
- UROY $5.60
- AVG Volume (30 Days)
- INZY 313.3K
- UROY 2.3M
- Earning Date
- INZY 11-05-2024
- UROY 12-11-2024
- Dividend Yield
- INZY N/A
- UROY N/A
- EPS Growth
- INZY N/A
- UROY N/A
- EPS
- INZY N/A
- UROY 0.05
- Revenue
- INZY N/A
- UROY $30,916,580.00
- Revenue This Year
- INZY N/A
- UROY N/A
- Revenue Next Year
- INZY N/A
- UROY $72.53
- P/E Ratio
- INZY N/A
- UROY $49.85
- Revenue Growth
- INZY N/A
- UROY 208.26
- 52 Week Low
- INZY $3.08
- UROY $1.86
- 52 Week High
- INZY $7.80
- UROY $3.76
- Technical
- Relative Strength Index (RSI)
- INZY 19.15
- UROY 42.64
- Support Level
- INZY $4.02
- UROY $2.62
- Resistance Level
- INZY $4.74
- UROY $2.76
- Average True Range (ATR)
- INZY 0.27
- UROY 0.16
- MACD
- INZY -0.11
- UROY -0.05
- Stochastic Oscillator
- INZY 2.65
- UROY 23.08
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.